Close Menu

Scope Fluidics: Carl Wittwer

Nov 02, 2020

Carl Wittwer has been appointed to the advisory committee of Scope Fluidics. Wittwer, who is credited as one of the creators of PCR, has specialized in developing ultra-rapid PCR chemistries and was a co-founder of BioFire Diagnostics. Wittwer will advise the Warsaw, Poland-based firm in the futher development of its 15-minute sample-to-answer multiplex PCR One system for which it is currently developing SARS-CoV-2 assays. 

More Like This

Apr 09, 2021

Micronoma: Jennifer Wargo

Micronoma, a company using signals from the tumor-related microbiome for liquid biopsy-based cancer diagnosis, has appointed Jennifer Wargo to its scientific advisory board. Wargo is a professor of surgical oncology and genomic medicine at the University of Texas MD Anderson Cancer Center.

Apr 08, 2021

Mission Bio: Yan Zhang, Charlie Silver

Single-cell analysis firm Mission Bio has appointed Yan Zhang as CEO.

Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she led that firm's commercial organization in China for genetic sciences and clinical next-generation sequencing and was general manager for its reproductive health and microarray businesses. Prior to Thermo, Zhang held product management and commercialization roles at Affymetrix, NuGen Technologies, and Molecular Devices. She holds a PhD in biochemistry from the Medical College of Wisconsin.

Former CEO Charlie Silver, a Mission Bio cofounder, will move into an advisory role.

Apr 06, 2021

Nautilus Biotechnology: Matt Murphy

Nautilus Biotechnology has appointed Matt Murphy as general counsel.

Murphy brings more than 25 years of experience as senior legal counsel for life sciences companies. He was previously VP and general counsel for both 10x Genomics and Pacific Biosciences and has advised companies including Caliper Technologies, BioElectron Technology, and Nanosys.

Murphy holds a law degree from the University of San Francisco.

Apr 06, 2021

NRGene: Keith Blanks, Richard Calk

NRGene has hired Keith Blanks as chief commercial officer and Richard Calk as chief strategy officer. Blanks previously was senior VP of sales and marketing at Calyxt, where he led the launch of one of the world's first gene-edited food products. Calk joins NRGene after serving as president and COO of Neogen. NRGene said that the two will help the Israeli company grow in North America.

Apr 05, 2021

Quadrant Biosciences: Brady Millican

Quadrant Biosciences announced Brady Millican has joined the firm as executive VP of sales. He has more than 30 years of experience in sales, marketing, business development, and operations in the medical diagnostics and prognostics space and was most recently chief business officer of Admera Health. Before that, he had senior level sales and marketing positions at Bostwick, Ameripath, and Dianon Laboratories. Based in Syracuse, New York, Quadrant has developed Clarifi ASD, a molecular saliva-based test for autism spectrum disorder, as well as Clarifi COVID-19, a saliva-based test codeveloped with the SUNY Upstate Medical University, which received Emergency Use Authorization from the US Food and Drug Administration in September.

Apr 05, 2021

Akoya Biosciences: Frederick Pla

Akoya Biosciences has appointed Frederic Pla as its chief operating officer. Pla most recently served as chief operating officer at the Parker Institute for Cancer Immunotherapy. Prior to this, Pla served as COO at Genomic Health before its acquisition by Exact Sciences in 2019. He has also served in leadership positions at Life Technologies, GE Healthcare, and NASA.

Apr 02, 2021

BioSkryb: Sean Keohane

BioSkryb has appointed Sean Keohane as senior vice president of commercial operations to spearhead commercialization of the company's ResolveDNA products for singe-cell whole-genome amplification. Keohane previously was VP of US marketing and sales at Numares. He has also previously held a variety of sales, marketing, and management positions at companies such as Molecular Devices, Thermo Fisher Scientific, Qiagen, Ciphergen Biosystems, Ventana Medical Systems, and Roche.

Apr 01, 2021

Applied DNA Sciences: Clay Shorrock

Clay Shorrock has been appointed as chief legal officer and executive director of business development at Applied DNA Sciences. He previously served as the company's in-house general and IP counsel from 2016 to 2019 and as outside general and IP counsel after that. Shorrock holds a JD with a concentration in IP from Seton Hall University Law School and a BA in biology from Franklin and Marshall College.

Mar 31, 2021

Tag.bio: Sanjay Padhi

Sanjay Padhi has joined Tag.bio as executive VP and chief technologist. He comes to the San Francisco-based data analytics startup from Amazon Web Services, where he was head of AWS research. Prior to that, he was a scientist at CERN. Padhi holds a PhD in high energy physics from McGill University.

Mar 31, 2021

Genome Medical: Brandon Poe, Marco Barcella, Russell Glass

South San Francisco-based digital health firm Genome Medical has made appointments to its management team and board of directors.

Brandon Poe has become the company's CFO. Previously, he was VP of finance at Illumina, and before that, CFO of medical device firm Sotera Wireless. He holds an MBA from the University of Chicago Booth School of Business and a bachelor's degree from Bucknell University.

Marco Barcella has been appointed as Genome Medical's chief product officer. Most recently, he held strategic product positions at Tiatros and at IBM Watson Health. He holds an MBA from the NYU Stern School of Business and a master of science degree from the University of Virginia.

Russell Glass has joined the firm as an independent director. He is the CEO of on-demand mental health company Ginger. Prior to that, he was the founder and CEO of Bizo, a B2B marketing and data firm that was sold to LinkedIn in 2014, which he then joined.

Mar 31, 2021

CareDx: Titte Srinivas, Steven Stone, Dustin Leach, Martyn Edney, More

CareDx has appointed Titte Srinivas as vice president of digital development and clinical integration, Steven Stone as VP of KidneyCare, Dustin Leach as VP of customer experience, and Martyn Edney as senior VP and head of human resources.

Srinivas is a transplant nephrologist who joins CareDx from University Hospitals in Cleveland, where he served as the chief of the division of nephrology and hypertension and Peter B. DeOreo Chair in Nephrology and Dialysis. Stone joins CareDx from from Myriad Genetics, where he served as VP of cancer genomics and developed products for personalized medicine in oncology. Leach joins CareDx from Teva Pharmaceuticals, where he most recently served as senior director of patient services – program development. Edney joins CareDx from Iqvia, where he served as VP of HR for the US and Canada.

The company also announced that it has promoted Marica Grskovic to VP of cell transplant therapy, and Jere Ramsey-Lester to VP of HR.

Grskovic joined CareDx nine years ago and has played a role in overseeing the design and development of the company's transplant diagnostic tests. Ramsey-Lester has been with CareDx since 2019, and has served as interim head of HR for the past year. She has held leadership positions in human resources at TreeHouse Foods, ConAgra Foods, and Fiserv.

Mar 31, 2021

Sera Prognostics: Robert Harrison

Pregnancy test firm Sera Prognostics has appointed Robert Harrison as chief information officer. For more than three decades, Harrison has served in senior leadership positions of both public and private companies. Most recently, he served as officer of Myriad Genetics' chief information office. With Myriad Genetics, he directed the information technology integration of four strategic acquisitions and helped facilitate its international business expansion over the past decade. Harrison is a member of the Association for Information Management Utah CIO Council and is a long-standing board member of the Utah Technology Council.

Mar 30, 2021

Evonetix: Michael Daniels

Michael Daniels has been appointed as head of product management at UK synthetic biology firm Evonetix. Previously, he was director of marketing and product management at Arcis Biotechnology, senior manager of marketing and business development at Cancer Research UK, and director of marketing and product management at Thermo Fisher Scientific. He holds a PhD in biochemistry and genetics from the University of Newcastle.

Mar 30, 2021

Oxford Nanopore Technologies: Tim Cowper, Jordan Herman

Tim Cowper has become CFO and Jordan Herman general counsel of Oxford Nanopore Technologies.

Chowper joined the company in 2012 as commercial operations director after acting as interim finance director for several months in 2009. He became VP of finance in 2017. Previously, he was finance director at British Biotech and at Clipper Ventures, he cofounded Sterilox, and he was financial controller at Celltech.

Herman joins Oxford Nanopore from Baker Botts, where he was a partner and acted as Oxford's outside counsel for more than a decade. He holds a JD from Ohio State University and a degree in political economy from Washington University.

Mar 30, 2021

Shivom: George Church

George Church has become a cofounder of Shivom, a London-based genomics and healthcare data analytics and platform provider. He is a professor of genetics at Harvard Medical School and a professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.